研究・業績について

Fukushima, T., Katsushima, U., Ogushi, N., Hase, K., & Nakano, J. (2024). Physical activity and prognosis and factors associated with low physical activity in patients with advanced or recurrent lung cancer: a retrospective, observational study. BMJ supportive & palliative care, spcare-2024-005122. Advance online publication. https://doi.org/10.1136/spcare-2024-005122

Nishioka, N., Hata, T., Yamada, T., Goto, Y., Amano, A., Negi, Y., Watanabe, S., Furuya, N., Oba, T., Ikoma, T., Nakao, A., Tanimura, K., Taniguchi, H., Yoshimura, A., Fukui, T., Murata, D., Kaira, K., Shiotsu, S., Hibino, M., Okada, A., … Takayama, K. (2024). Impact of TTF-1 Expression on the Prognostic Prediction of Patients with NSCLC with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs Chemoimmunotherapy: A Multicenter, Retrospective Study. Cancer research and treatment, 10.4143/crt.2024.748. Advance online publication. https://doi.org/10.4143/crt.2024.748

Yamanaka, Y., Ota, T., Masuoka, Y., Takeyasu, Y., Nakamura, S., Terashima, M., Yoshioka, H., Fukuoka, M., & Kurata, T. (2024). Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer. Cancers, 16(18), 3127. https://doi.org/10.3390/cancers16183127

Yoshioka, H., Ishida, T., Atagi, S., Tamiya, A., Nishimura, T., Iwamoto, Y., Kanehara, M., Kim, Y. H., Korogi, Y., Tomii, K., Katakami, N., Komuta, K., Nishikawa, M., Gemma, A., Yamaki, K., Kawahara, M., Miyakoshi, C., & Mio, T. (2024). Randomized Phase II Trial of Amrubicin Plus Irinotecan Versus Cisplatin Plus Irinotecan in Chemo-naïve Patients With Extensive-Disease Small-Cell Lung Cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01. Clinical lung cancer, S1525-7304(24)00197-9. Advance online publication. https://doi.org/10.1016/j.cllc.2024.09.004

Okuma, Y., Nomura, S., Sakakibara-Konishi, J., Tsukita, Y., Murakami, S., Hosomi, Y., Tambo, Y., Kogure, Y., Yoshioka, H., Tamiya, M., Ninomiya, K., & Iwama, E. (2024). Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas. Clinical lung cancer, 25(4), 389–394. https://doi.org/10.1016/j.cllc.2024.02.002

Yagishita, S., Yamanaka, Y., Kurata, T., Watanabe, K., Hosomi, Y., Horinouchi, H., Ohe, Y., Nakahara, Y., Naoki, K., Asao, T., Takahashi, K., Saeki, S., Sakagami, T., Nakashima, K., Tsubata, Y., Fujita, Y., Wakui, H., Furuta, M., Konishi, J. S., Ohuchi, M., … Hamada, A. (2024). Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older. Clinical pharmacology and therapeutics, 116(4), 1042–1051. https://doi.org/10.1002/cpt.3339

Watanabe, S., Yoshioka, H., Sakai, H., Hotta, K., Takenoyama, M., Yamada, K., Sugawara, S., Takiguchi, Y., Hosomi, Y., Tomii, K., Niho, S., Nishio, M., Kato, T., Takahashi, T., Ebi, H., Aono, M., Yamamoto, N., Ohe, Y., & Nakagawa, K. (2024). Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM. ESMO open, 9(4), 102975. https://doi.org/10.1016/j.esmoop.2024.102975

Yoshimura, A., Takeda, T., Kataoka, N., Tanimura, K., Fukui, M., Chihara, Y., Takei, S., Kawachi, H., Nakanishi, K., Yamanaka, Y., Tamiya, N., Honda, R., Okura, N., Yamada, T., Uryu, K., Murai, J., Shiotsu, S., Yoshioka, H., Yamada, T., Kurata, T., … Takayama, K. (2024). Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study. Frontiers in oncology, 14, 1303543. https://doi.org/10.3389/fonc.2024.1303543

Takeyasu, Y., Yoshida, T., Masuda, K., Matsumoto, Y., Shinno, Y., Okuma, Y., Goto, Y., Horinouchi, H., Yamamoto, N., & Ohe, Y. (2024). Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations. JTO clinical and research reports, 5(2), 100636. https://doi.org/10.1016/j.jtocrr.2024.100636

Sekino, Y., Hishida, T., Yoshioka, H., Wakabayashi, M., Mitome, N., Shiono, S., Kenmotsu, H., Nosaki, K., Aokage, K., Horinouchi, H., Fukuda, H., Ohe, Y., Watanabe, S. I., & Lung Cancer Surgical Study Group (LCSSG) and the Lung Cancer Study Group (LCSG) of the Japan Clinical Oncology Group (JCOG) (2024). Protocol summary of a randomized phase III study: comparing systemic therapy with and without debulking surgery (primary tumour resection) for clinical stage IVA (cT1-2bN0-1M1a) non-small cell lung cancer with radiologically undetermined pleural dissemination JCOG2103 (DEBULK-LUNG). Japanese journal of clinical oncology, hyae143. Advance online publication. https://doi.org/10.1093/jjco/hyae143

Watanabe, S. I., Yotsukura, M., Miyoshi, T., Hattori, A., Isaka, T., Maniwa, T., Isaka, M., Yoshioka, H., Endo, M., Mimae, T., Tsutani, Y., Nakagawa, K., Aokage, K., & Lung Cancer Surgical Study Group (LCSSG) of the Japan Clinical Oncology Group (JCOG) (2024). Updated review of perioperative treatment for non-small-cell lung cancer in the new era of immune checkpoint inhibitors: past, present, and future. Japanese journal of clinical oncology, hyae106. Advance online publication. https://doi.org/10.1093/jjco/hyae106

Nakagawa, K., Yotsukura, M., Mimae, T., Hattori, A., Miyoshi, T., Isaka, M., Endo, M., Tsutani, Y., Isaka, T., Maniwa, T., Nakajima, R., Yoshioka, H., Takei, H., Aokage, K., & Watanabe, S. I. (2024). The Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group: outstanding contribution and entering a new phase. Japanese journal of clinical oncology, hyae100. Advance online publication. https://doi.org/10.1093/jjco/hyae100

Katsushima, U., Hase, K., Fukushima, T., Kubo, T., Nakano, J., Ogushi, N., Okuno, Y., Kamisako, K., Nakanishi, K., Okazaki, Y., Ikoma, T., Takeyasu, Y., Yamanaka, Y., Yoshioka, H., Imai, Y., & Kurata, T. (2024). Investigation of a practical assessment index to capture the clinical presentation of cachexia in patients with lung cancer. Japanese journal of clinical oncology, 54(3), 305–311. https://doi.org/10.1093/jjco/hyad177

Takamori, S., Yatabe, Y., Osoegawa, A., Aokage, K., Yoshioka, H., Miyoshi, T., Mimae, T., Endo, M., Hattori, A., Yotsukura, M., Isaka, T., Isaka, M., Maniwa, T., Nakajima, R., & Watanabe, S. I. (2024). Rare but clinically important salivary gland-type tumor of the lung: A review. Japanese journal of clinical oncology, 54(2), 121–128. https://doi.org/10.1093/jjco/hyad154

Watanabe, K., Sasaki, K., Machida, R., Shimizu, J., Yamane, Y., Tamiya, M., Saito, S., Takada, Y., Yoh, K., Yoshioka, H., Murakami, H., Kitazono, S., Goto, Y., Horinouchi, H., & Ohe, Y. (2024). High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group). Japanese journal of clinical oncology, 54(10), 1084–1092. https://doi.org/10.1093/jjco/hyae094

Garon, E. B., Lu, S., Goto, Y., De Marchi, P., Paz-Ares, L., Spigel, D. R., Thomas, M., Yang, J. C., Ardizzoni, A., Barlesi, F., Orlov, S., Yoshioka, H., Mountzios, G., Khanna, S., Bossen, C., Carbini, M., Turri, S., Myers, A., & Cho, B. C. (2024). Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42(2), 180–191. https://doi.org/10.1200/JCO.23.00910

Maniwa, T., Okami, J., Miyoshi, T., Wakabayashi, M., Yoshioka, H., Mimae, T., Endo, M., Hattori, A., Nakagawa, K., Isaka, T., Isaka, M., Kita, R., Sekino, Y., Mitome, N., Aokage, K., Saji, H., Nakajima, R., Okada, M., Tsuboi, M., Asamura, H., … West Japan Oncology Group and Japan Clinical Oncology Group (2024). Lymph node dissection in small peripheral lung cancer: Supplemental analysis of JCOG0802/WJOG4607L. The Journal of thoracic and cardiovascular surgery, 168(3), 674–683.e1. https://doi.org/10.1016/j.jtcvs.2023.11.023

Nakagawa, K., Watanabe, S. I., Wakabayashi, M., Yotsukura, M., Mimae, T., Hattori, A., Miyoshi, T., Isaka, M., Endo, M., Yoshioka, H., Tsutani, Y., Isaka, T., Maniwa, T., Nakajima, R., Suzuki, K., Aokage, K., Saji, H., Tsuboi, M., Okada, M., Asamura, H., … Fukuda, H. (2024). Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, S1556-0864(24)02376-1. Advance online publication. https://doi.org/10.1016/j.jtho.2024.10.002

Gadgeel, S. M., Rodríguez-Abreu, D., Halmos, B., Garassino, M. C., Kurata, T., Cheng, Y., Jensen, E., Shamoun, M., Rajagopalan, K., & Paz-Ares, L. (2024). Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 19(8), 1228–1241. https://doi.org/10.1016/j.jtho.2024.04.011

Shiraishi, Y., Nomura, S., Sugawara, S., Horinouchi, H., Yoneshima, Y., Hayashi, H., Azuma, K., Hara, S., Niho, S., Morita, R., Yamaguchi, M., Yokoyama, T., Yoh, K., Kurata, T., Okamoto, H., Okamoto, M., Kijima, T., Kasahara, K., Fujiwara, Y., Murakami, S., … Okamoto, I. (2024). Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial. The Lancet. Respiratory medicine, 12(11), 877–887. https://doi.org/10.1016/S2213-2600(24)00185-1

Hata, A., Katakami, N., Takase, N., Kibata, K., Yamanaka, Y., Tamiya, M., Mori, M., Kijima, T., Morita, S., Sakai, K., & Nishio, K. (2024). Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study. Lung cancer (Amsterdam, Netherlands), 197, 107988. https://doi.org/10.1016/j.lungcan.2024.107988

Asao, T., Shukuya, T., Uemura, K., Kitadai, R., Yamamoto, G., Mouri, A., Tamaoka, M., Imai, R., Tsukita, Y., Isobe, K., Watanabe, S., Kamimura, M., Morita, R., Kudo, K., Inomata, M., Tateishi, K., Kakinuma, K., Yoshioka, H., Namba, Y., Sumiyoshi, I., … Takahashi, K. (2024). Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047). Lung cancer (Amsterdam, Netherlands), 194, 107894. https://doi.org/10.1016/j.lungcan.2024.107894

Cho, B. C., Lu, S., Felip, E., Spira, A. I., Girard, N., Lee, J. S., Lee, S. H., Ostapenko, Y., Danchaivijitr, P., Liu, B., Alip, A., Korbenfeld, E., Mourão Dias, J., Besse, B., Lee, K. H., Xiong, H., How, S. H., Cheng, Y., Chang, G. C., Yoshioka, H., … MARIPOSA Investigators (2024). Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. The New England journal of medicine, 391(16), 1486–1498. https://doi.org/10.1056/NEJMoa2403614

Yamaguchi, O., Mori, K., Takata, S., Shibata, K., Chikamori, K., Kimura, N., Nagai, Y., Nakagawa, T., Igawa, S., Harada, T., Yoshioka, H., Tanaka, H., Nogawa, H., Satoh, H., Shiozawa, T., Tsuji, K., Kobayashi, K., & Kaira, K. (2024). Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study). Thoracic cancer, 15(2), 163–171. https://doi.org/10.1111/1759-7714.15173

岡崎 優太, 倉田 宝保 2024/03 治療法の再整理とアップデートのために　専門家による私の治療　小細胞肺癌 日本医事新報 (5214):34-35

岡崎 優太, 吉岡 弘鎮, 上硲 敬介, 奥野 祐希子, 中西 健太郎, 生駒 龍興, 竹安 優貴, 勝島 詩恵, 山中 雄太, 倉田 宝保 2024/04 神経症状を契機に診断された傍腫瘍性神経症候群関連抗体陽性の小細胞肺癌の2例 肺癌 64(2):124-132 10.2482/haigan.64.124

Miura, S., Koh, Y., Azuma, K., Yoshioka, H., Koyama, K., Teraoka, S., Ishii, H., Kibata, K., Ozawa, Y., Tokito, T., Oyanagi, J., Shimokawa, T., Kurata, T., Yamamoto, N., & Tanaka, H. (2023). Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial. BMC cancer, 23(1), 6. https://doi.org/10.1186/s12885-022-10467-w

Torasawa, M., Yoshida, T., Takeyasu, Y., Shimoda, Y., Tateishi, A., Matsumoto, Y., Masuda, K., Shinno, Y., Okuma, Y., Goto, Y., Horinouchi, H., Yamamoto, N., Takahashi, K., & Ohe, Y. (2023). Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients. Cancer medicine, 12(11), 12388–12401. https://doi.org/10.1002/cam4.5939

Ikoma, T., Shimokawa, M., Matsumoto, T., Boku, S., Yasuda, T., Shibata, N., Kurioka, Y., Takatani, M., Nobuhisa, T., Namikawa, T., Kitagawa, H., Hanazaki, K., Doi, K., Shimada, T., Tsumura, T., Marusawa, H., Kanaya, S., Morita, S., Inokuma, T., Nagai, H., … Satake, H. (2023). Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab. Cancer immunology, immunotherapy : CII, 72(2), 427–435. https://doi.org/10.1007/s00262-022-03265-7

Sugawara, S., Tanaka, K., Imamura, F., Yamamoto, N., Nishio, M., Okishio, K., Hirashima, T., Tanaka, H., Fukuhara, T., Nakahara, Y., Kurata, T., Katakami, N., Okada, M., Horinouchi, H., Udagawa, H., Kasahara, K., Satouchi, M., Saka, H., Tokito, T., Hosomi, Y., … Kato, T. (2023). Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407. Cancer science, 114(8), 3330–3341. https://doi.org/10.1111/cas.15816

Takeda, T., Yamada, T., Kunimatsu, Y., Tanimura, K., Morimoto, K., Shiotsu, S., Chihara, Y., Okada, A., Horiuchi, S., Hibino, M., Uryu, K., Honda, R., Yamanaka, Y., Yoshioka, H., Kurata, T., & Takayama, K. (2023). Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study. Cancers, 15(5), 1543. https://doi.org/10.3390/cancers15051543

Tanimura, K., Takeda, T., Kataoka, N., Yoshimura, A., Nakanishi, K., Yamanaka, Y., Yoshioka, H., Honda, R., Uryu, K., Fukui, M., Chihara, Y., Takei, S., Kawachi, H., Yamada, T., Tamiya, N., Okura, N., Yamada, T., Murai, J., Shiotsu, S., Kurata, T., … Takayama, K. (2023). First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study. Cancers, 15(20), 4988. https://doi.org/10.3390/cancers15204988

Miyoshi, T., Ito, H., Wakabayashi, M., Hashimoto, T., Sekino, Y., Suzuki, K., Tsuboi, M., Moriya, Y., Yoshino, I., Isaka, T., Hattori, A., Mimae, T., Isaka, M., Maniwa, T., Endo, M., Yoshioka, H., Nakagawa, K., Nakajima, R., Tsutani, Y., Saji, H., … Watanabe, S. I. (2023). Risk factors for loss of pulmonary function after wedge resection for peripheral ground-glass opacity dominant lung cancer. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 64(6), ezad365. https://doi.org/10.1093/ejcts/ezad365

Cheng, Y., Yang, J. C., Okamoto, I., Zhang, L., Hu, J., Wang, D., Hu, C., Zhou, J., Wu, L., Cao, L., Liu, J., Zhang, H., Sun, H., Wang, Z., Gao, H., Yan, Y., Xiao, S., Lin, J., Pietanza, M. C., & Kurata, T. (2023). Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia. Immunotherapy, 15(13), 1029–1044. https://doi.org/10.2217/imt-2023-0043

Tachihara, M., Tsujino, K., Ishihara, T., Hayashi, H., Sato, Y., Kurata, T., Sugawara, S., Shiraishi, Y., Teraoka, S., Azuma, K., Daga, H., Yamaguchi, M., Kodaira, T., Satouchi, M., Shimokawa, M., Yamamoto, N., Nakagawa, K., & West Japan Oncology Group (WJOG) (2023). Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial. JAMA oncology, 9(11), 1505–1513. https://doi.org/10.1001/jamaoncol.2023.3309

Hazama, D., Nakahama, K., Kodama, H., Miyazaki, A., Azuma, K., Kawashima, Y., Sato, Y., Ito, K., Shiraishi, Y., Miura, K., Takahama, T., Oizumi, S., Namba, Y., Ikeda, S., Yoshioka, H., Tsuya, A., Yasuda, Y., Negi, Y., Hara, A., Toda, M., … Tachihara, M. (2023). Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma. JTO clinical and research reports, 5(1), 100613. https://doi.org/10.1016/j.jtocrr.2023.100613

Kogure, Y., Kada, A., Hashimoto, H., Atagi, S., Takiguchi, Y., Saka, H., Ebi, N., Inoue, A., Kurata, T., Fujita, Y., Nishii, Y., Itani, H., Endo, T., Saito, A. M., Shibayama, T., Yamamoto, N., & Gemma, A. (2023). Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study. JTO clinical and research reports, 4(6), 100514. https://doi.org/10.1016/j.jtocrr.2023.100514

Goto, Y., Kenmotsu, H., Tamiya, M., Murakami, S., Kurata, T., Yanagitani, N., Taniguchi, H., Kuyama, S., Shimizu, J., Yokoyama, T., Shimada, N., Maeda, T., Tamiya, A., Uchiyama, A., Imaizumi, K., Takahama, T., Kato, T., Hayashi, H., Shiraiwa, N., Toyoizumi, S., … Nishio, M. (2023). A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan. JTO clinical and research reports, 4(5), 100508. https://doi.org/10.1016/j.jtocrr.2023.100508

Murata, Y., Tanzawa, S., Misumi, T., Yoshioka, H., Miyauchi, E., Ninomiya, K., Takeshita, M., Ito, K., Okamoto, T., Sugawara, S., Kawashima, Y., Hashimoto, K., Mori, M., Miyanaga, A., Hayashi, A., Tanaka, H., Honda, R., Nojiri, M., Sato, Y., Hata, A., … Seki, N. (2023). Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study. JTO clinical and research reports, 4(12), 100593. https://doi.org/10.1016/j.jtocrr.2023.100593

Ikoma, T., Matsumoto, T., Boku, S., Yasuda, T., Masuda, M., Ito, T., Nakamaru, K., Yamaki, S., Nakayama, S., Hashimoto, D., Yamamoto, T., Shibata, N., Ikeura, T., Naganuma, M., Satoi, S., & Kurata, T. (2023). A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer. Journal of clinical medicine, 12(10), 3477. https://doi.org/10.3390/jcm12103477

Garassino, M. C., Gadgeel, S., Speranza, G., Felip, E., Esteban, E., Dómine, M., Hochmair, M. J., Powell, S. F., Bischoff, H. G., Peled, N., Grossi, F., Jennens, R. R., Reck, M., Hui, R., Garon, E. B., Kurata, T., Gray, J. E., Schwarzenberger, P., Jensen, E., Pietanza, M. C., … Rodríguez-Abreu, D. (2023). Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(11), 1992–1998. https://doi.org/10.1200/JCO.22.01989

Ishiura, Y., Nomura, S., Ishii, Y., Imai, K., Nakahama, K., Sawai, Y., Tamaki, T., Shimizu, T., Miyashita, N., & Ito, T. (2023). Alectinib in a patient with ALK-positive non-small lung cancer unable to swallow capsules. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 29(5), 1283–1285. https://doi.org/10.1177/10781552231155374

Aokage, K., Suzuki, K., Saji, H., Wakabayashi, M., Kataoka, T., Sekino, Y., Fukuda, H., Endo, M., Hattori, A., Mimae, T., Miyoshi, T., Isaka, M., Yoshioka, H., Nakajima, R., Nakagawa, K., Okami, J., Ito, H., Kuroda, H., Tsuboi, M., Okumura, N., … Japan Clinical Oncology Group (2023). Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial. The Lancet. Respiratory medicine, 11(6), 540–549. https://doi.org/10.1016/S2213-2600(23)00041-3

Akagi, K., Yagishita, S., Ohuchi, M., Hayashi, Y., Takeyasu, Y., Masuda, K., Shinno, Y., Okuma, Y., Yoshida, T., Goto, Y., Horinouchi, H., Yamamoto, N., Mukae, H., Ohe, Y., & Hamada, A. (2023). Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 178, 247–253. https://doi.org/10.1016/j.lungcan.2023.03.001

Yamamoto, H., Soh, J., Okumura, N., Suzuki, H., Nakata, M., Fujiwara, T., Gemba, K., Sano, I., Fujinaga, T., Kataoka, M., Terazaki, Y., Fujimoto, N., Kataoka, K., Kosaka, S., Yamashita, M., Inokawa, H., Inoue, M., Nakamura, H., Yamashita, Y., Hotta, K., … Toyooka, S. (2023). Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201. PloS one, 18(5), e0285273. https://doi.org/10.1371/journal.pone.0285273

Hashimoto, D., Sakaguchi, T., Satoi, S., Yamamoto, T., Yamaki, S., Ishida, M., Matsui, Y., Shibata, N., Boku, S., Katsushima, U., Ikeura, T., & Sekimoto, M. (2023). Survival impact of occult liver metastasis and peritoneal dissemination compared with radiologically defined distant organ metastasis in pancreatic ductal adenocarcinoma. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 23(1), 73–81. https://doi.org/10.1016/j.pan.2022.11.012

Tanaka, T., Yoshida, T., Masuda, K., Takeyasu, Y., Shinno, Y., Matsumoto, Y., Okuma, Y., Goto, Y., Horinouchi, H., Yamamoto, N., & Ohe, Y. (2023). Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies. Respiratory investigation, 61(1), 74–81. https://doi.org/10.1016/j.resinv.2022.10.003

Fujimoto, D., Miura, S., Tomii, K., Sumikawa, H., Yoshimura, K., Wakuda, K., Oya, Y., Yokoyama, T., Kijima, T., Asao, T., Tamiya, M., Nakamura, A., Yoshioka, H., Tokito, T., Murakami, S., Tamiya, A., Yokouchi, H., Watanabe, S., Yamaguchi, O., Morinaga, R., … Yamamoto, N. (2023). Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer. Scientific reports, 13(1), 3698. https://doi.org/10.1038/s41598-023-30676-y

Matsumoto, T., Ikoma, T., Yamamura, S., Miura, K., Tsuduki, T., Watanabe, T., Nagai, H., Takatani, M., & Yasui, H. (2023). Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab. Scientific reports, 13(1), 2433. https://doi.org/10.1038/s41598-023-29706-6

Ishii, H., Azuma, K., Shimose, T., Yoshioka, H., Kurata, T., Shingu, N., Okamoto, M., Kawashima, Y., & Okamoto, I. (2023). Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003). Thoracic cancer, 14(1), 105–107. https://doi.org/10.1111/1759-7714.14727

Nakamura, T., Yoshida, T., Takeyasu, Y., Masuda, K., Sinno, Y., Matsumoto, Y., Okuma, Y., Goto, Y., Horinouchi, H., Yamamoto, N., & Ohe, Y. (2023). Distinct metastatic spread and progression patterns in patients treated with crizotinib for ROS1- and ALK-rearranged non-small cell lung cancer: a single-center retrospective study. Translational lung cancer research, 12(7), 1436–1444. https://doi.org/10.21037/tlcr-23-10

Nishio, M., Atagi, S., Goto, K., Hosomi, Y., Seto, T., Hida, T., Nakagawa, K., Yoshioka, H., Nogami, N., Maemondo, M., Nagase, S., Okamoto, I., Yamamoto, N., Igawa, Y., Tajima, K., Fukuoka, M., Yamamoto, N., & Nishio, K. (2023). Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+non-small-cell lung cancer. Translational lung cancer research, 12(6), 1167–1184. https://doi.org/10.21037/tlcr-22-632

延山 誠一 2023/12 【あなたも名医!ひとりでできるアレルギー診療　Total allergist的診療の手引き】(第4章)症状から考えるアレルギー診療　咳嗽jmed mook(89):100-102

中西 健太郎, 山中 雄太, 吉岡 弘鎮 2023/05 【水バランスの異常としてのdysnatremia】呼吸器疾患における低Na血症と治療 糖尿病・内分泌代謝科 56(5):568-576

池田 夢, 吉岡 弘鎮, 岡崎 優太, 中西 健太郎, 後藤 清里, 生駒 龍興, 深井 真璃, 竹安 優貴, 山中 雄太, 中村 聡明, 倉田 宝保 2023/08 Nivolumab+Ipilimumab併用療法によって生じたradiation recall pneumonitisの1例 肺癌63(4):319-32410.2482/haigan.63.319

Kaneda, T., Kurata, T., Yoshida, T., Kibata, K., Yoshioka, H., Yanagimoto, H., Takeda, K., Yoshida, T., & Tsuta, K. (2022). Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer. BMC cancer, 22(1), 154. https://doi.org/10.1186/s12885-022-09264-2

Kumagai, S., Koyama, S., Itahashi, K., Tanegashima, T., Lin, Y. T., Togashi, Y., Kamada, T., Irie, T., Okumura, G., Kono, H., Ito, D., Fujii, R., Watanabe, S., Sai, A., Fukuoka, S., Sugiyama, E., Watanabe, G., Owari, T., Nishinakamura, H., Sugiyama, D., … Nishikawa, H. (2022). Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer cell, 40(2), 201–218.e9. https://doi.org/10.1016/j.ccell.2022.01.001

Sakata, S., Otsubo, K., Yoshida, H., Ito, K., Nakamura, A., Teraoka, S., Matsumoto, N., Shiraishi, Y., Haratani, K., Tamiya, M., Ikeda, S., Miura, S., Tanizaki, J., Omori, S., Yoshioka, H., Hata, A., Yamamoto, N., & Nakagawa, K. (2022). Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L. Cancer science, 113(1), 221–228. https://doi.org/10.1111/cas.15176

Yamamoto, T., Satoi, S., Yamaki, S., Hashimoto, D., Ishida, M., Ikeura, T., Hirooka, S., Matsui, Y., Boku, S., Nakayama, S., Nakamaru, K., Shibata, N., Katsushima, U., & Sekimoto, M. (2022). Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Cancers, 14(5), 1354. https://doi.org/10.3390/cancers14051354

Matsumoto, T., Yamamura, S., Ikoma, T., Kurioka, Y., Doi, K., Yasuda, T., Boku, S., Kawai, T., Shibata, N., Nagai, H., Tsuduki, T., Shimada, T., Matsumoto, Y., Tsumura, T., Takatani, M., Yasui, H., & Satake, H. (2022). Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study. Clinical Medicine Insights. Oncology, 16, 11795549221137135. https://doi.org/10.1177/11795549221137135

Yoneshima, Y., Morita, S., Ando, M., Nakamura, A., Iwasawa, S., Yoshioka, H., Goto, Y., Takeshita, M., Harada, T., Hirano, K., Oguri, T., Kondo, M., Miura, S., Hosomi, Y., Kato, T., Kubo, T., Kishimoto, J., Yamamoto, N., Nakanishi, Y., & Okamoto, I. (2022). Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment. Clinical lung cancer, 23(7), 585–592. https://doi.org/10.1016/j.cllc.2022.08.011

Haratake, N., Hayashi, H., Shimokawa, M., Nakano, Y., Azuma, K., Oki, M., Ota, K., Yoshioka, H., Sakamoto, T., Yamamoto, N., Nakagawa, K., & Seto, T. (2022). Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L). Clinical lung cancer, 23(3), e257–e263. https://doi.org/10.1016/j.cllc.2021.10.007

Nakamura, T., Watari, T., Ohshima, S., Katsushima, U., & Muro, S. (2022). Sjögren's Syndrome Complicated With Sarcoidosis With a Repetitive, Prolonged, Non-productive Cough. Cureus, 14(3), e22827. https://doi.org/10.7759/cureus.22827

Hotta, K., Hida, T., Nokihara, H., Morise, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Kumagai, T., Watanabe, S., Goto, K., Satouchi, M., Kozuki, T., Shukuya, T., Nakagawa, K., Mitsudomi, T., Yamamoto, N., Asakawa, T., … Tamura, T. (2022). Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer. ESMO open, 7(4), 100527. https://doi.org/10.1016/j.esmoop.2022.100527

Shiotsu, S., Yoshimura, A., Yamada, T., Morimoto, K., Tsuchiya, M., Yoshioka, H., Hiranuma, O., Chihara, Y., Yamada, T., Hasegawa, I., Ohta, T., Takeda, T., Hiraoka, N., & Takayama, K. (2022). Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study. Frontiers in oncology, 12, 904644. https://doi.org/10.3389/fonc.2022.904644

Boku, S., Satake, H., Ohta, T., Mitani, S., Kawakami, K., Suzuki, Y., Matsumoto, T., Terazawa, T., Yamazaki, E., Hasegawa, H., Ikoma, T., Uemura, M., Yamaguchi, T., Naito, A., Ishizuka, Y., Kurokawa, Y., Sakai, D., Kawakami, H., Shimokawa, T., Tsujinaka, T., … Kagawa, Y. (2022). TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III BRAF V600E-mutated colorectal cancer. Future oncology (London, England), 18(38), 4153–4160. https://doi.org/10.2217/fon-2022-0949

Nakasya, A., Hagiwara, Y., Ikoma, T., Kurioka, Y., Matsumoto, T., Yamamoto, Y., Tsuduki, T., Kajiwara, T., Moriwaki, T., Nishina, T., Yamashita, N., & Hyodo, I. (2022). Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study). International journal of clinical oncology, 27(4), 684–694. https://doi.org/10.1007/s10147-022-02114-y

Haratake, N., Shimokawa, M., Seto, T., Yoshioka, H., Yamamoto, N., Nakagawa, K., & Mitsudomi, T. (2022). Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405). International journal of clinical oncology, 27(9), 1404–1412. https://doi.org/10.1007/s10147-022-02193-x

Omori, S., Harada, H., Mori, K., Hisamatsu, Y., Tsuboguchi, Y., Yoshioka, H., Morinaga, R., Daga, H., Kurata, T., & Takahashi, T. (2022). Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Investigational new drugs, 40(1), 106–114. https://doi.org/10.1007/s10637-021-01155-w

Seto, T., Nosaki, K., Shimokawa, M., Toyozawa, R., Sugawara, S., Hayashi, H., Murakami, H., Kato, T., Niho, S., Saka, H., Oki, M., Yoshioka, H., Okamoto, I., Daga, H., Azuma, K., Tanaka, H., Nishino, K., Tohnai, R., Yamamoto, N., & Nakagawa, K. (2022). Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). Journal for immunotherapy of cancer, 10(2), e004025. https://doi.org/10.1136/jitc-2021-004025

Takeyasu, Y., Yoshida, T., Masuda, K., Matsumoto, Y., Shinno, Y., Okuma, Y., Goto, Y., Horinouchi, H., Yamamoto, N., & Ohe, Y. (2022). Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib. JTO clinical and research reports, 3(5), 100311. https://doi.org/10.1016/j.jtocrr.2022.100311

Takeyasu, Y., Yoshida, T., Masuda, K., Matsumoto, Y., Shinno, Y., Okuma, Y., Goto, Y., Horinouchi, H., Yamamoto, N., & Ohe, Y. (2022). Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib. JTO clinical and research reports, 3(5), 100311. https://doi.org/10.1016/j.jtocrr.2022.100311

Hagiwara, Y., Nakasya, A., Matsumoto, T., Ikoma, T., Yamamoto, Y., Kurioka, Y., Tsuduki, T., Kajiwara, T., Nishina, T., Yamashita, N., Moriwaki, T., & Hyodo, I. (2022). Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study. Journal of gastrointestinal oncology, 13(6), 2769–2778. https://doi.org/10.21037/jgo-22-499

Matsumoto, T., Yamamura, S., Ikoma, T., Kurioka, Y., Doi, K., Boku, S., Shibata, N., Nagai, H., Shimada, T., Tsuduki, T., Tsumura, T., Takatani, M., Yasui, H., & Satake, H. (2022). Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study. Journal of clinical medicine, 11(8), 2247. https://doi.org/10.3390/jcm11082247

Ikoma, T., Matsumoto, T., Kurioka, Y., Takatani, M., Nagai, H., Matsumoto, Y., Satake, H., & Yasui, H. (2022). Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy. Journal of clinical medicine, 11(20), 6100. https://doi.org/10.3390/jcm11206100

Tada, H., Mitsudomi, T., Misumi, T., Sugio, K., Tsuboi, M., Okamoto, I., Iwamoto, Y., Sakakura, N., Sugawara, S., Atagi, S., Takahashi, T., Hayashi, H., Okada, M., Inokawa, H., Yoshioka, H., Takahashi, K., Higashiyama, M., Yoshino, I., Nakagawa, K., & West Japan Oncology Group (2022). Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(3), 231–241. https://doi.org/10.1200/JCO.21.01729

Spigel, D. R., Faivre-Finn, C., Gray, J. E., Vicente, D., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Garassino, M. C., Hui, R., Quantin, X., Rimner, A., Wu, Y. L., Özgüroğlu, M., Lee, K. H., Kato, T., de Wit, M., Kurata, T., Reck, M., Cho, B. C., Senan, S., … Antonia, S. J. (2022). Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(12), 1301–1311. https://doi.org/10.1200/JCO.21.01308

Nakamura, T., Takeyasu, Y., Yoshida, T., Ohashi, K., & Ohe, Y. (2022). End-of-life impact of concurrent diabetes mellitus and adrenal insufficiency as immune-related adverse events in an advanced non-small cell lung cancer patient. Thoracic cancer, 13(21), 3073–3075. https://doi.org/10.1111/1759-7714.14660

Utsumi, T., Taniguchi, Y., Noda, Y., Fukai, M., Kibata, K., & Murakawa, T. (2022). SMARCA4-deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: A case report. Thoracic cancer, 13(15), 2264–2266. https://doi.org/10.1111/1759-7714.14547

Asami, K., Ando, M., Nishimura, T., Yokoi, T., Tamura, A., Minato, K., Mori, M., Ogushi, F., Yamamoto, A., Yoshioka, H., Kawahara, M., & Atagi, S. (2022). A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01). Thoracic cancer, 13(12), 1827–1836. https://doi.org/10.1111/1759-7714.14465

勝島 詩恵, 今井 芳枝, 橋本 理恵子, 三木 恵美, 荒堀 広美, 井上 勇太, 長谷 公隆 2022 外来でがんリハビリテーションを受ける再発・進行がん患者の経験 Palliative Care Research 17(4):127-134

大石 かほり[中濱], 野村 昌作 2022/07 【徹底ガイドDICのすべて　2022-'23】病態生理と病理　細胞外膜小胞体(extracellular vesicle) 救急･集中治療 34(2):555-561

岡崎 優太, 吉岡 弘鎮 2022/12 【肺がん・頭頸部がん】非小細胞肺がんにおけるオリゴ転移,オリゴ再発に対する治療戦略 腫瘍内科 30(6):614-620

竹安 優貴, 倉田 宝保 2022/07 【がん免疫療法の展望:免疫チェックポイント阻害薬の併用療法に中心に】免疫チェックポイント阻害薬の併用療法のエビデンス　分子標的療法と免疫チェックポイント阻害薬 腫瘍内科 30(1):18-22

勝島 詩恵, 中野 治郎, 福島 卓矢, 久保 峰鳴, 森 拓也, 長谷 公隆, 倉田 宝保 2022/11 肺がん治療におけるリハビリテーションとチーム医療　外来通院治療を行う肺がん患者に対するリハビリテーションの現状と課題 肺癌 62(6): Page521

Rodríguez-Abreu, D., Powell, S. F., Hochmair, M. J., Gadgeel, S., Esteban, E., Felip, E., Speranza, G., De Angelis, F., Dómine, M., Cheng, S. Y., Bischoff, H. G., Peled, N., Reck, M., Hui, R., Garon, E. B., Boyer, M., Kurata, T., Yang, J., Pietanza, M. C., Souza, F., … Garassino, M. C. (2021). Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Annals of oncology : official journal of the European Society for Medical Oncology, 32(7), 881–895. https://doi.org/10.1016/j.annonc.2021.04.008 Faivre-Finn, C., Vicente, D., Kurata, T., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Spigel, D. R., Garassino, M. C., Reck, M., Senan, S., Naidoo, J., Rimner, A., Wu, Y. L., Gray, J. E., Özgüroğlu, M., Lee, K. H., Cho, B. C., Kato, T., de Wit, M., Newton, M., … Antonia, S. J. (2021). Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 16(5), 860–867. https://doi.org/10.1016/j.jtho.2020.12.015 Yoh, K., Hirashima, T., Saka, H., Kurata, T., Ohe, Y., Hida, T., Mellemgaard, A., Verheijen, R. B., Ou, X., Ahmed, G. F., Hayama, M., Sugibayashi, K., & Oxnard, G. R. (2021). Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. Targeted oncology, 16(3), 339–355. https://doi.org/10.1007/s11523-021-00806-5 Powell, S. F., Rodríguez-Abreu, D., Langer, C. J., Tafreshi, A., Paz-Ares, L., Kopp, H. G., Rodríguez-Cid, J., Kowalski, D. M., Cheng, Y., Kurata, T., Awad, M. M., Lin, J., Zhao, B., Pietanza, M. C., Piperdi, B., & Garassino, M. C. (2021). Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 16(11), 1883–1892. https://doi.org/10.1016/j.jtho.2021.06.020 Satouchi, M., Nosaki, K., Takahashi, T., Nakagawa, K., Aoe, K., Kurata, T., Sekine, A., Horiike, A., Fukuhara, T., Sugawara, S., Umemura, S., Saka, H., Okamoto, I., Yamamoto, N., Sakai, H., Kishi, K., Katakami, N., Horinouchi, H., Hida, T., Okamoto, H., … Hotta, K. (2021). First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. Cancer science, 112(12), 5000–5010. https://doi.org/10.1111/cas.15144 Horinouchi, H., Nogami, N., Saka, H., Nishio, M., Tokito, T., Takahashi, T., Kasahara, K., Hattori, Y., Ichihara, E., Adachi, N., Noguchi, K., Souza, F., & Kurata, T. (2021). Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study. Cancer science, 112(8), 3255–3265. https://doi.org/10.1111/cas.14980 Yoneshima, Y., Morita, S., Ando, M., Nakamura, A., Iwasawa, S., Yoshioka, H., Goto, Y., Takeshita, M., Harada, T., Hirano, K., Oguri, T., Kondo, M., Miura, S., Hosomi, Y., Kato, T., Kubo, T., Kishimoto, J., Yamamoto, N., Nakanishi, Y., & Okamoto, I. (2021). Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 16(9), 1523–1532. https://doi.org/10.1016/j.jtho.2021.03.027 Fujimoto, D., Miura, S., Yoshimura, K., Wakuda, K., Oya, Y., Yokoyama, T., Yokoi, T., Asao, T., Tamiya, M., Nakamura, A., Yoshioka, H., Haratani, K., Teraoka, S., Tokito, T., Murakami, S., Tamiya, A., Itoh, S., Yokouchi, H., Watanabe, S., Yamaguchi, O., … Yamamoto, N. (2021). Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. European journal of cancer (Oxford, England : 1990), 150, 63–72. https://doi.org/10.1016/j.ejca.2021.03.016

Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., Shah, R., Cobo, M., Lee, K. H., Cheema, P., Tiseo, M., John, T., Lin, M. C., Imamura, F., Kurata, T., Todd, A., … FLAURA Investigators (2020). Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. The New England journal of medicine, 382(1), 41–50. https://doi.org/10.1056/NEJMoa1913662 Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M. J., Clingan, P., Powell, S. F., Cheng, S. Y., Bischoff, H. G., Peled, N., Grossi, F., Jennens, R. R., Reck, M., Garon, E. B., Novello, S., Rubio-Viqueira, B., Boyer, M., … Garassino, M. C. (2020). Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(14), 1505–1517. https://doi.org/10.1200/JCO.19.03136 Seto, T., Azuma, K., Yamanaka, T., Sugawara, S., Yoshioka, H., Wakuda, K., Atagi, S., Iwamoto, Y., Hayashi, H., Okamoto, I., Saka, H., Mitsuoka, S., Fujimoto, D., Nishino, K., Horiike, A., Daga, H., Sone, T., Yamamoto, N., Nakagawa, K., & Nakanishi, Y. (2020). Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(8), 793–803. https://doi.org/10.1200/JCO.19.01494 Yoshioka, H., Kato, T., Okamoto, I., Tanaka, H., Hida, T., Seto, T., Kiura, K., Tian, Y., Azuma, H., & Yamamoto, N. (2020). Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3. Future oncology (London, England), 16(4), 49–60. https://doi.org/10.2217/fon-2019-0659

Yoshioka, H., Shimokawa, M., Seto, T., Morita, S., Yatabe, Y., Okamoto, I., Tsurutani, J., Satouchi, M., Hirashima, T., Atagi, S., Shibata, K., Saito, H., Toyooka, S., Yamamoto, N., Nakagawa, K., & Mitsudomi, T. (2019). Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 30(12), 1978–1984. https://doi.org/10.1093/annonc/mdz399 Hayashi, H., Kurata, T., Takiguchi, Y., Arai, M., Takeda, K., Akiyoshi, K., Matsumoto, K., Onoe, T., Mukai, H., Matsubara, N., Minami, H., Toyoda, M., Onozawa, Y., Ono, A., Fujita, Y., Sakai, K., Koh, Y., Takeuchi, A., Ohashi, Y., Nishio, K., … Nakagawa, K. (2019). Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37(7), 570–579. https://doi.org/10.1200/JCO.18.00771 Niki, M., Nakaya, A., Kurata, T., Nakahama, K., Yoshioka, H., Kaneda, T., Kibata, K., Ogata, M., & Nomura, S. (2019). Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report. Molecular and clinical oncology, 10(2), 267–269. https://doi.org/10.3892/mco.2018.1777

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y. C., Karapetis, C. S., Hiret, S., Ostoros, G., … PACIFIC Investigators (2018). Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. The New England journal of medicine, 379(24), 2342–2350. https://doi.org/10.1056/NEJMoa1809697 Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., Cheng, S. Y., Bischoff, H. G., Peled, N., Grossi, F., Jennens, R. R., Reck, M., Hui, R., Garon, E. B., Boyer, M., Rubio-Viqueira, B., … KEYNOTE-189 Investigators (2018). Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. The New England journal of medicine, 378(22), 2078–2092. https://doi.org/10.1056/NEJMoa1801005 Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B. C., Cheng, Y., Cho, E. K., Voon, P. J., Planchard, D., Su, W. C., Gray, J. E., Lee, S. M., … FLAURA Investigators (2018). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. The New England journal of medicine, 378(2), 113–125. https://doi.org/10.1056/NEJMoa1713137 Niki, M., Nakaya, A., Kurata, T., Yoshioka, H., Kaneda, T., Kibata, K., Ogata, M., & Nomura, S. (2018). Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. Oncotarget, 9(64), 32298–32304. https://doi.org/10.18632/oncotarget.25949 Nakaya, A., Kurata, T., Yoshioka, H., Takeyasu, Y., Niki, M., Kibata, K., Satsutani, N., Ogata, M., Miyara, T., & Nomura, S. (2018). Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. International journal of clinical oncology, 23(4), 634–640. https://doi.org/10.1007/s10147-018-1250-2 Ramalingam, S. S., Yang, J. C., Lee, C. K., Kurata, T., Kim, D. W., John, T., Nogami, N., Ohe, Y., Mann, H., Rukazenkov, Y., Ghiorghiu, S., Stetson, D., Markovets, A., Barrett, J. C., Thress, K. S., & Jänne, P. A. (2018). Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36(9), 841–849. https://doi.org/10.1200/JCO.2017.74.7576 Kaneda, T., Yoshioka, H., Tamiya, M., Tamiya, A., Hata, A., Okada, A., Niwa, T., Shiroyama, T., Kanazu, M., Ishida, T., & Katakami, N. (2018). Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. BMC cancer, 18(1), 6. https://doi.org/10.1186/s12885-017-3952-7

Govindan, R., Szczesna, A., Ahn, M. J., Schneider, C. P., Gonzalez Mella, P. F., Barlesi, F., Han, B., Ganea, D. E., Von Pawel, J., Vladimirov, V., Fadeeva, N., Lee, K. H., Kurata, T., Zhang, L., Tamura, T., Postmus, P. E., Jassem, J., O'Byrne, K., Kopit, J., Li, M., … Reck, M. (2017). Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(30), 3449–3457. https://doi.org/10.1200/JCO.2016.71.7629 Peters, S., Gettinger, S., Johnson, M. L., Jänne, P. A., Garassino, M. C., Christoph, D., Toh, C. K., Rizvi, N. A., Chaft, J. E., Carcereny Costa, E., Patel, J. D., Chow, L. Q. M., Koczywas, M., Ho, C., Früh, M., van den Heuvel, M., Rothenstein, J., Reck, M., Paz-Ares, L., Shepherd, F. A., … Felip, E. (2017). Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(24), 2781–2789. https://doi.org/10.1200/JCO.2016.71.9476